The U.S. Food and Drug Administration announced it will work with manufacturers to remove boxed warnings from hormone replacement therapies used for menopause, concluding earlier risk estimates were overstated. The agency’s move follows fresh evidence and public briefings; HHS officials and FDA leadership framed the change as expanding access to menopausal treatment while cautioning continued evaluation of long‑term outcomes. Manufacturers will submit label change applications; clinicians and patient groups are preparing for updated prescribing conversations. The decision affects a widely used drug class and may shift treatment patterns for symptomatic menopause, while regulators emphasize that the decision does not imply broader preventive benefits beyond approved indications.